Analysts are closely watching the upcoming release of Phase III data on Erbitux as a treatment for pancreatic cancer. ImClone and Bristol-Myers Squibb are hoping to add pancreatic cancer to the label for Erbitux, which is currently approved for head and neck and colon cancer. OSI Pharmaceuticals will be paying attention as well, as Erbitux could emerge as a competitor for Tarceva. An approval could be worth an estimated $100 million to $250 million, reports The Street, while negative data would threaten $50 million in off-label use of the drug. The data is expected in late March or early April.
- check out this report for more
Related Articles:
Erbitux approved for head and neck cancers. Report
ImClone touts increased survival rate in Erbitux cancer trial. Report
Erbitux data backs use as front-line therapy. Report